Current Advances in the Treatment of Fibrolamellar Carcinoma of Liver

References

• Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956;91:168–186. doi:10.1001/archpedi.1956.02060020170015
   PubMedGoogle Scholar
• Limaiem F, Bouhamed M, Sahraoui G, et al. Hepatocellular carcinoma: a clinicopathological study of 64 cases. Pan Afr Med J. 2017;27:41. doi:10.11604/pamj.2017.27.41.9584
   PubMedGoogle Scholar
• Eggert T, McGlynn KA, Duffy A, et al. Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10. Gut. 2013;62:1667–1668. doi:10.1136/gutjnl-2013-305164
   PubMed Web of Science ®Google Scholar
• Polychronidis G, Feng J, Murtha-Lemekhova A, et al. Factors influencing overall survival for patients with fibrolamellar hepatocellular carcinoma: analysis of the surveillance, epidemiology, and end results database. Int J Gen Med. 2022;15:393–406. doi:10.2147/IJGM.S338066
   PubMed Web of Science ®Google Scholar
• Ramai D, Ofosu A, Lai JK, et al. Fibrolamellar hepatocellular carcinoma: a population-based observational study. Dig Dis Sci. 2021;66(1):308–314. doi:10.1007/s10620-020-06135-3
   PubMed Web of Science ®Google Scholar
• Lafaro KJ, Pawlik TM. Fibrolamellar hepatocellular carcinoma: current clinical perspectives. J Hepatocell Carcinoma. 2015;2:151–157. doi:10.2147/JHC.S75153
   PubMedGoogle Scholar
• Lemekhova A, Hornuss D, Polychronidis G, et al. Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience. World J Surg Oncol. 2020;18:93. doi:10.1186/s12957-020-01855-2
   PubMed Web of Science ®Google Scholar
• Dinh TA, Utria AF, Barry KC, et al. A framework for fibrolamellar carcinoma research and clinical trials. Nat Rev Gastroenterol Hepatol. 2022;19:328–342. doi:10.1038/s41575-022-00580-3
   PubMed Web of Science ®Google Scholar
• Chen KY, Popovic A, Hsiehchen D, et al. Clinical outcomes in fibrolamellar hepatocellular carcinoma treated with immune checkpoint inhibitors. Cancers. 2022;14(21):5347. doi:10.3390/cancers14215347
   PubMed Web of Science ®Google Scholar
• Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014;343:1010–1014. doi:10.1126/science.1249484
   PubMed Web of Science ®Google Scholar
• Graham RP, Lackner C, Terracciano L, et al. Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion. Hepatology. 2018;68:1441–1447. doi:10.1002/hep.29719
   PubMed Web of Science ®Google Scholar
• Surjan RCT, Santos ESD, Silveira SDP, et al. Fibrolamellar hepatocellular carcinoma-related hyperammonemic encephalopathy: up to now and next steps. Clin Mol Hepatol. 2020;26:231–232. doi:10.3350/cmh.2019.0084
   PubMed Web of Science ®Google Scholar
• Vyas M, Hechtman JF, Zhang Y, et al. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Mod Pathol. 2020;33(4):648–656. doi:10.1038/s41379-019-0398-2
   PubMed Web of Science ®Google Scholar
• El Dika I, Bowman AS, Berger MF, et al. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. Cancer. 2020;126:4126–4135. doi:10.1002/cncr.32960
   PubMed Web of Science ®Google Scholar
• Darcy DG, Chiaroni-Clarke R, Murphy JM, et al. The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients. Oncotarget. 2015;6:755–770. doi:10.18632/oncotarget.2712
   PubMed Web of Science ®Google Scholar
• Cornella H, Alsinet C, Sayols S, et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology. 2015;148:806–18.e10. doi:10.1053/j.gastro.2014.12.028
   PubMed Web of Science ®Google Scholar
• Dinh TA, Sritharan R, Smith FD, et al. Hotspots of aberrant enhancer activity in fibrolamellar carcinoma reveal candidate oncogenic pathways and therapeutic vulnerabilities. Cell Rep. 2020;31:107509. doi:10.1016/j.celrep.2020.03.073
   PubMed Web of Science ®Google Scholar
• Karki A, Putra J, Kim SS, et al. MDM4 expression in fibrolamellar hepatocellular carcinoma. Oncol Rep. 2019;42:1487–1496. doi:10.3892/or.2019.7241
   PubMed Web of Science ®Google Scholar
• Lim II, Farber BA, LaQuaglia MP. Advances in fibrolamellar hepatocellular carcinoma: a review. Eur J Pediatr Surg. 2014;24:461–466. doi:10.1055/s-0034-1396420
   PubMed Web of Science ®Google Scholar
• Ross HM, Daniel HD, Vivekanandan P, et al. Fibrolamellar carcinomas are positive for CD68. Mod Pathol. 2011;24:390–395. doi:10.1038/modpathol.2010.207
   PubMed Web of Science ®Google Scholar
• Ward SC, Huang J, Tickoo SK, et al. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol. 2010;23(9):1180–1190. doi:10.1038/modpathol.2010.105
   PubMed Web of Science ®Google Scholar
• Akce M, Vence LM, Blando JM, et al. Immune analysis of fibrolamellar hepatocellular carcinoma. J Clin Oncol. 2017;35:324. doi:10.1200/JCO.2017.35.4_suppl.324
   Google Scholar
• Abdelhamed W, El-Kassas M. Fibrolamellar hepatocellular carcinoma: a rare but unpleasant event. World J Gastrointest Oncol. 2022;14:1103–1114. doi:10.4251/wjgo.v14.i6.1103
   PubMed Web of Science ®Google Scholar
• Graham RP, Yeh MM, Lam-Himlin D, et al. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Mod Pathol. 2018;31:141–149. doi:10.1038/modpathol.2017.103
   PubMed Web of Science ®Google Scholar
• Smith M, Tomboc PJ, Markovich B. Fibrolamellar Hepatocellular Carcinoma. Treasure Island (FL): StatPearls; 2022.
   Google Scholar
• Berkovitz A, Migler RD, Qureshi A, et al. Clinical and demographic predictors of survival for fibrolamellar carcinoma patients—A patient community, registry-based study. Hepatol Commun. 2022;6(12):3539–3549. doi:10.1002/hep4.2105
   PubMed Web of Science ®Google Scholar
• Di Federico A, Rizzo A, Carloni R, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs. 2022;31:361–369. doi:10.1080/13543784.2022.2009455
   PubMed Web of Science ®Google Scholar
• Rizzo A, Cusmai A, Gadaleta-Caldarola G, et al. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? Expert Rev Gastroenterol Hepatol. 2022;16:333–339. doi:10.1080/17474124.2022.2064273
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Di Federico A, et al. Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: where do we stand? Front Oncol. 2021;11:803133. doi:10.3389/fonc.2021.803133
   PubMed Web of Science ®Google Scholar
• Viscardi G, Tralongo AC, Massari F, et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer. 2022;177:175–185. doi:10.1016/j.ejca.2022.09.031
   PubMed Web of Science ®Google Scholar
• Chaudhari VA, Khobragade K, Bhandare M, et al. Management of fibrolamellar hepatocellular carcinoma. Chin Clin Oncol. 2018;7(5):51. doi:10.21037/cco.2018.08.08
   PubMed Web of Science ®Google Scholar
• Darcy DG, Malek MM, Kobos R, et al. Prognostic factors in fibrolamellar hepatocellular carcinoma in young people. J Pediatr Surg. 2015;50:153–156. doi:10.1016/j.jpedsurg.2014.10.039
   PubMed Web of Science ®Google Scholar
• Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106:1331–1338. doi:10.1002/cncr.21703
   PubMed Web of Science ®Google Scholar
• Kakar S, Burgart LJ, Batts KP, et al. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 2005;18(11):1417–1423. doi:10.1038/modpathol.3800449
   PubMed Web of Science ®Google Scholar
• Wahab MA, El Hanafy E, El Nakeeb A, et al. Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period). World J Gastrointest Surg. 2017;9(2):61–67. doi:10.4240/wjgs.v9.i2.61
   PubMed Web of Science ®Google Scholar
• Schultz SP, Holtestaul T, Marenco CW, et al. Prognostic role of lymph node sampling in adolescent and young adults with fibrolamellar carcinoma. J Surg Res. 2022;276:261–271. doi:10.1016/j.jss.2022.03.006
   PubMed Web of Science ®Google Scholar
• Polychronidis G, Murtha-Lemekhova A, Fuchs J, et al. A multidisciplinary approach to the management of fibrolamellar carcinoma: current perspectives and future prospects. Onco Targets Ther. 2022;15:1095–1103. doi:10.2147/OTT.S296127
   PubMed Web of Science ®Google Scholar
• Yamashita S, Vauthey JN, Kaseb AO, et al. Prognosis of fibrolamellar carcinoma compared to non-cirrhotic conventional hepatocellular carcinoma. J Gastrointest Surg. 2016;20:1725–1731. doi:10.1007/s11605-016-3216-x
   PubMed Web of Science ®Google Scholar
• Kassahun WT. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol. 2016;14:151. doi:10.1186/s12957-016-0903-8
   PubMed Web of Science ®Google Scholar
• Solipuram V, Baretti M, Kim AY, et al. Surgical debulking for refractory hyperammonemic encephalopathy in fibrolamellar hepatocellular carcinoma. Hepatology. 2021;74:2899–2901. doi:10.1002/hep.31998
   PubMed Web of Science ®Google Scholar
• Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997;26:877–883. doi:10.1002/hep.510260412
   PubMed Web of Science ®Google Scholar
• Mavros MN, Mayo SC, Hyder O, et al. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg. 2012;215(6):820–830. doi:10.1016/j.jamcollsurg.2012.08.001
   PubMed Web of Science ®Google Scholar
• Njei B, Konjeti VR, Ditah I. Prognosis of patients with fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis. Gastrointest Cancer Res. 2014;7:49–54.
   PubMedGoogle Scholar
• Atienza LG, Berger J, Mei X, et al. Liver transplantation for fibrolamellar hepatocellular carcinoma: a national perspective. J Surg Oncol. 2017;115:319–323. doi:10.1002/jso.24515
   PubMed Web of Science ®Google Scholar
• Weeda VB, Murawski M, McCabe AJ, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma – results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer. 2013;49:2698–2704. doi:10.1016/j.ejca.2013.04.012
   PubMed Web of Science ®Google Scholar
• Gras P, Truant S, Boige V, et al. Prolonged complete response after GEMOX chemotherapy in a patient with advanced fibrolamellar hepatocellular carcinoma. Case Rep Oncol. 2012;5:169–172. doi:10.1159/000338242
   PubMedGoogle Scholar
• Kaseb AO, Shama M, Sahin IH, et al. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology. 2013;85:197–203. doi:10.1159/000354698
   PubMed Web of Science ®Google Scholar
• Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003;21:421–427. doi:10.1200/JCO.2003.10.103
   PubMed Web of Science ®Google Scholar
• Gottlieb S, O’Grady C, Gliksberg A, et al. Early experiences with triple immunochemotherapy in adolescents and young adults with high-risk fibrolamellar carcinoma. Oncology. 2021;99(5):310–317. doi:10.1159/000513358
   PubMed Web of Science ®Google Scholar
• Peacock JG, Call JA, Olivier KR. Radiotherapy for metastatic fibrolamellar hepatocellular carcinoma. Rare Tumors. 2013;5:e28. doi:10.4081/rt.2013.e28
   PubMedGoogle Scholar
• Yeung R, Beaton L, Rackley T, et al. Stereotactic body radiotherapy for small unresectable hepatocellular carcinomas. Clin Oncol. 2019;31:365–373. doi:10.1016/j.clon.2019.01.012
   Web of Science ®Google Scholar
• Mafeld S, French J, Tiniakos D, et al. Fibrolamellar hepatocellular carcinoma: treatment with Yttrium-90 and subsequent surgical resection. Cardiovasc Intervent Radiol. 2018;41:816–820. doi:10.1007/s00270-018-1903-6
   PubMed Web of Science ®Google Scholar
• Aguado A, Ristagno R, Towbin AJ, et al. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children. Pediatr Blood Cancer. 2019;66:e27510. doi:10.1002/pbc.27510
   PubMed Web of Science ®Google Scholar
• Hawkins CM, Kukreja K, Geller JI, et al. Radioembolisation for treatment of pediatric hepatocellular carcinoma. Pediatr Radiol. 2013;43(7):876–881. doi:10.1007/s00247-012-2568-y
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Al Zahrani A, Alfakeeh A. Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports. J Med Case Rep. 2021;15:132. doi:10.1186/s13256-021-02695-8
   PubMedGoogle Scholar
• Bauer U, Mogler C, Braren RF, et al. Progression after immunotherapy for fibrolamellar carcinoma. Visceral Med. 2019;35:39–42. doi:10.1159/000497464
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Tella SH, Kommalapati A, et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol. 2019;10:554–561. doi:10.21037/jgo.2019.01.35
   PubMed Web of Science ®Google Scholar
• Berger R, Dinstag G, Tirosh O, et al. Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab. J Immunother Cancer. 2022;10(12):e005620. doi:10.1136/jitc-2022-005620
   PubMed Web of Science ®Google Scholar
• El Dika I, Mayer RJ, Venook AP, et al. A multicenter randomized three‐arm Phase II study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in patients with unresectable fibrolamellar carcinoma. Oncologist. 2020;25:925–e1603. doi:10.1634/theoncologist.2020-0367
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Mayer R, Venook AP, et al. Phase II multicenter, open-label study of oral ENMD-2076 for the treatment of patients with advanced fibrolamellar carcinoma. Oncologist. 2020;25:e1837–e1845. doi:10.1634/theoncologist.2020-0093
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Zhang J, et al. Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC). J Clin Oncol. 2021;39:310. doi:10.1200/JCO.2021.39.3_suppl.310
   Web of Science ®Google Scholar
• Lalazar G, Requena D, Ramos-Espiritu L, et al. Identification of novel therapeutic targets for fibrolamellar carcinoma using patient-derived xenografts and direct-from-patient screening. Cancer Discov. 2021;11:2544–2563. doi:10.1158/2159-8290.CD-20-0872
   PubMed Web of Science ®Google Scholar
• Toyota A, Goto M, Miyamoto M, et al. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model. Biochem Biophys Res Commun. 2022;621:157–161. doi:10.1016/j.bbrc.2022.07.008
   PubMed Web of Science ®Google Scholar
• Neumayer C, Ng D, Jiang CS, et al. Oncogenic addiction of Fibrolamellar hepatocellular carcinoma to the fusion kinase DNAJB1-PRKACA. Clin Cancer Res. 2022;29(1):271–278.
   Web of Science ®Google Scholar
• Shebl B, Ng D, Lalazar G, et al. Targeting BCL-XL in fibrolamellar hepatocellular carcinoma. JCI Insight. 2022;7. doi:10.1172/jci.insight.161820
   PubMed Web of Science ®Google Scholar